Hospital

Technology gains traction in health-system pharmacies for drug inventory and to automate applications.

Mirvetuximab soravtansine-gynx (Elahere; ImmunoGen Inc) approved FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Approximately 80% of all HIV infections among teens are from the gay and bisexual population.

Study suggests states maintaining higher health care expenditures are more attentive to price transparency initiatives and tend to adopt all-payer claims databases.

NVX-CoV2373 is a protein-based vaccine developed from the genetic sequence of the first strain of SARS-CoV-2.

Dapagliflozin and standard of care found to slow the decline in kidney function and lower the incidence of kidney failure.

New COVID-19 variants are always cause for concern but are not a cause for panic.

PrEP reduces the risk of getting HIV from sex by about 99% for certain patient population with consistent adherence.

Zilucoplan is a subcutaneous, self-administered peptide inhibitor of complement component 5.

Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.

Despite evidence of a higher risk of myocarditis or pericarditis with COVID-19 vaccination, immunization should still be recommended because the benefits likely outweigh the harms, study shows.

Direct-acting antivirals have high efficacy for hepatitis C, however, patients with advanced liver scarring are at risk for the development of secondary diseases.

New continuous glucose monitor systems provide additional support and quality of life improvements for patients with diabetes.

States with a higher prevalence of Medicaid patients with type 2 diabetes were found to have lower use ratio of glucose-lowering agents with known cardiovascular benefits.

Under specific circumstances and criteria, they are adjustable to approximate OS in selected populations of Canadian patients who have advanced non–small cell lung cancer.

Analysis indicates that a 25-mg dose reduces the condition scores significantly more than a 1mg dose over a 3-week period, but the 10-mg dose did not yield the same results.

Tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy approved for the treatment of adults with metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.

Intravenous immunoglobulin is used for several autoimmune and inflammatory conditions, although researchers have not fully understood its specific mechanisms.

FDA approves brentuximab vedotin for the treatment of patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

The most common cause of death for patients with non-alcoholic fatty liver disease is cardiovascular disease, but it also increases the risk of hepatocellular carcinoma and may surpass hepatitis B and C as the leading cause of this cancer.

Cerebral adrenoleukodystrophy is a progressive neurodegenerative disease causes irreversible neurologic decline and can result in functional disabilities, such hearing loss and cortical blindness.

Pharmacists and health care providers should be familiar with the management of xylazine overdose and withdrawal.

Study shows there are 2.5 times more breast cancer survivors since the last estimate was conducted in 2007.

A physician working in the field of palliative care discusses how pharmacists and physicians can work together to help address issues pertaining to polypharmacy through deprescribing.

FDA committee voted that trial data do not support the benefits outweighing the risks in patients aged 12 to 17 years and children aged 4 to 11 years for the use of albuterol/budesonide in the treatment of asthma.

Improvement is seen with a higher suspicion of disease and extended timelines, analysis demonstrates.

Katrina Skinner is the president of the Alabama Chapter of the American Academy of Pediatrics.

These show promise as markers to help identify individuals with the conditions and develop targeted therapeutic options.